Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Esophageal Neoplasms 1

Interventions

Cyclophosphamide 909Carboplatin 786Paclitaxel 741pembrolizumab 741Bevacizumab 715Cisplatin 707Gemcitabine 621Docetaxel 583Rituximab 558Radiotherapy 546Dexamethasone 510Nivolumab 488Doxorubicin 445Fluorouracil 392Capecitabine 382Etoposide 357Pemetrexed 336Oxaliplatin 335Cytarabine 334Lenalidomide 327Prednisone 327Erlotinib Hydrochloride 323fludarabine phosphate 315Trastuzumab 305Leucovorin 299fludarabine 296Vincristine 288Bortezomib 284Filgrastim 284Cetuximab 275

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Histocompatibility Testing × Clear all
NCT00319735 2016-04-28

Cetuximab and Radiation Therapy for Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas

Hoosier Cancer Research Network

Phase 2 Completed
41 enrolled 18 charts
Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡